Multicenter Randomized Single Blind Study of the Clinical Efficacy and Safety of GNR-060 (JSC "GENERIUM", Russia) Compared to Metalyse (Boehringer Ingelheim Pharma GmbH & Co.KG, Germany) in Patients With ST Elevation Myocardial Infarction
Latest Information Update: 11 Mar 2024
At a glance
- Drugs Tenecteplase (Primary)
- Indications Myocardial infarction
- Focus Registrational; Therapeutic Use
- Sponsors GENERIUM Pharmaceuticals
Most Recent Events
- 05 Mar 2024 Planned End Date changed from 13 Dec 2023 to 1 Oct 2024.
- 05 Mar 2024 Planned primary completion date changed from 29 Sep 2023 to 1 Oct 2024.
- 08 Nov 2022 New trial record